Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts. more
Time Frame | SCPH | Sector | S&P500 |
---|---|---|---|
1-Week Return | -9.97% | -3.39% | 0.2% |
1-Month Return | -2.99% | -1.92% | 2.72% |
3-Month Return | -41.02% | -10.54% | 7.31% |
6-Month Return | -20.15% | -4.47% | 10.44% |
1-Year Return | -44.92% | 4.06% | 27.53% |
3-Year Return | -32.99% | 0.94% | 30.88% |
5-Year Return | -36.65% | 36.67% | 89.21% |
10-Year Return | -76.95% | 102.87% | 199.95% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | 2.06M | 13.59M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":15.18,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 364.00K | 399.00K | 438.00K | 468.00K | 3.81M | [{"date":"2019-12-31","value":9.55,"profit":true},{"date":"2020-12-31","value":10.47,"profit":true},{"date":"2021-12-31","value":11.49,"profit":true},{"date":"2022-12-31","value":12.28,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (364.00K) | (399.00K) | (438.00K) | (468.00K) | 9.78M | [{"date":"2019-12-31","value":-3.72,"profit":false},{"date":"2020-12-31","value":-4.08,"profit":false},{"date":"2021-12-31","value":-4.48,"profit":false},{"date":"2022-12-31","value":-4.78,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | - | - | - | (22.69%) | 71.96% | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-31.52,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 32.91M | 29.93M | 25.82M | 36.16M | 65.18M | [{"date":"2019-12-31","value":50.48,"profit":true},{"date":"2020-12-31","value":45.93,"profit":true},{"date":"2021-12-31","value":39.62,"profit":true},{"date":"2022-12-31","value":55.47,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (32.91M) | (29.93M) | (25.82M) | (36.16M) | (55.40M) | [{"date":"2019-12-31","value":-3290500000,"profit":false},{"date":"2020-12-31","value":-2993300000,"profit":false},{"date":"2021-12-31","value":-2582300000,"profit":false},{"date":"2022-12-31","value":-3615700000,"profit":false},{"date":"2023-12-31","value":-5539600000,"profit":false}] |
Total Non-Operating Income/Expense | (198.00K) | (4.55M) | (4.74M) | (2.78M) | (2.58M) | [{"date":"2019-12-31","value":-19800000,"profit":false},{"date":"2020-12-31","value":-454800000,"profit":false},{"date":"2021-12-31","value":-473700000,"profit":false},{"date":"2022-12-31","value":-278000000,"profit":false},{"date":"2023-12-31","value":-257500000,"profit":false}] |
Pre-Tax Income | (33.00M) | (32.21M) | (28.03M) | (36.84M) | (54.81M) | [{"date":"2019-12-31","value":-3299600000,"profit":false},{"date":"2020-12-31","value":-3220900000,"profit":false},{"date":"2021-12-31","value":-2803400000,"profit":false},{"date":"2022-12-31","value":-3683800000,"profit":false},{"date":"2023-12-31","value":-5481000000,"profit":false}] |
Income Taxes | 1.42M | 2.18M | 2.45M | 681.00K | 458.11K | [{"date":"2019-12-31","value":57.87,"profit":true},{"date":"2020-12-31","value":89.07,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":27.77,"profit":true},{"date":"2023-12-31","value":18.68,"profit":true}] |
Income After Taxes | (34.41M) | (34.39M) | (30.49M) | (37.52M) | (55.27M) | [{"date":"2019-12-31","value":-3441500000,"profit":false},{"date":"2020-12-31","value":-3439300000,"profit":false},{"date":"2021-12-31","value":-3048600000,"profit":false},{"date":"2022-12-31","value":-3751900000,"profit":false},{"date":"2023-12-31","value":-5526810500,"profit":false}] |
Income From Continuous Operations | (33.00M) | (32.21M) | (28.03M) | (36.84M) | (50.25M) | [{"date":"2019-12-31","value":-3299600000,"profit":false},{"date":"2020-12-31","value":-3220900000,"profit":false},{"date":"2021-12-31","value":-2803400000,"profit":false},{"date":"2022-12-31","value":-3683800000,"profit":false},{"date":"2023-12-31","value":-5024600000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (34.41M) | (34.39M) | (30.49M) | (37.52M) | (54.81M) | [{"date":"2019-12-31","value":-3441500000,"profit":false},{"date":"2020-12-31","value":-3439300000,"profit":false},{"date":"2021-12-31","value":-3048600000,"profit":false},{"date":"2022-12-31","value":-3751900000,"profit":false},{"date":"2023-12-31","value":-5481000000,"profit":false}] |
EPS (Diluted) | (1.77) | (1.32) | (1.03) | (1.30) | (1.42) | [{"date":"2019-12-31","value":-177,"profit":false},{"date":"2020-12-31","value":-132,"profit":false},{"date":"2021-12-31","value":-103,"profit":false},{"date":"2022-12-31","value":-130,"profit":false},{"date":"2023-12-31","value":-142,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
SCPH | |
---|---|
Cash Ratio | 5.99 |
Current Ratio | 8.08 |
Quick Ratio | 6.89 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
SCPH | |
---|---|
ROA (LTM) | -42.02% |
ROE (LTM) | -166.89% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
SCPH | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.75 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.25 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
SCPH | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 5.37 |
P/B | 5.21 |
Price/FCF | NM |
EV/R | 4.00 |
EV/Ebitda | NM |
Scpharmaceuticals Inc (SCPH) share price today is $3.353
Yes, Indians can buy shares of Scpharmaceuticals Inc (SCPH) on Vested. To buy Scpharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in SCPH stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Scpharmaceuticals Inc (SCPH) via the Vested app. You can start investing in Scpharmaceuticals Inc (SCPH) with a minimum investment of $1.
You can invest in shares of Scpharmaceuticals Inc (SCPH) via Vested in three simple steps:
The 52-week high price of Scpharmaceuticals Inc (SCPH) is $6.71. The 52-week low price of Scpharmaceuticals Inc (SCPH) is $3.08.
The price-to-earnings (P/E) ratio of Scpharmaceuticals Inc (SCPH) is
The price-to-book (P/B) ratio of Scpharmaceuticals Inc (SCPH) is 5.21
The dividend yield of Scpharmaceuticals Inc (SCPH) is 0.00%
The market capitalization of Scpharmaceuticals Inc (SCPH) is $162.63M
The stock symbol (or ticker) of Scpharmaceuticals Inc is SCPH